Clinical Trial Update: Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pucotenlimab in combination with vorolanib as neoadjuvant therapy for clear cell renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Pucotenlimab
• Vorolanib (vorolanib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Status: RECRUITING